Sex steroids and endothelial function: translating basic science to clinical practice

Trends in Pharmacological Sciences

Volumn 28, Issue 6, 2007, Pages 263-270

  Miller, Virginia M ^a,b   Mulvagh, Sharon L ^a  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CONJUGATED ESTROGEN; ENDOTHELIUM DERIVED RELAXING FACTOR; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; NITRIC OXIDE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; TESTOSTERONE;

ARTERY CALCIFICATION; ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL REACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HUMAN; MALE; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOSIS; VASODILATATION; VEIN THROMBOSIS;

ANIMALS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ESTROGENS; GONADAL STEROID HORMONES; HUMANS; PROGESTERONE; RECEPTORS, ESTROGEN; TESTOSTERONE;

EID: 34249297914     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.04.004     Document Type: Review

References (70)

1. Mendelsohn M.E., and Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 308 (2005) 1583-1587
2. Hisamoto K., and Bender J.R. Vascular cell signaling by membrane estrogen receptors. Steroids 70 (2005) 382-387
3. Bell C. Estrogen-induced sensitization of the uterine artery of the guinea pig to acetylcholine. Br. J. Pharmacol. 49 (1973) 595-601
4. Furchgott R.F., and Zawadski J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
5. Miller V.M., and Vanhoutte P.M. Endothelium-dependent vascular responsiveness: evolutionary aspects. In: Ryan U., and Rubanyi G.M. (Eds). Endothelial Regulation of Vascular Tone (1992), Marcel Dekker, Inc. 3-20
6. Lind L. Lipids and endothelium-dependent vasodilation - a review. Lipids 37 (2002) 1-15
7. Prasad A., et al. Predisposition to atherosclerosis by infections. Role of endothelial dysfunction. Circulation 106 (2002) 184-190
8. Gisclard V., et al. Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. J. Pharmacol. Exp. Ther. 244 (1988) 19-22
9. O'Rourke S., et al. Vascular pharmacology. In: Creager M.A., et al. (Ed). Vascular Medicine: A Companion to Braunwald's Heart Disease (2006), Elsevier 71-100
10. Mikkola T.S., et al. Postmenopausal hormone therapy before and after the women's health initiative study: what consequences?. Ann. Med. 36 (2004) 402-413
11. McCredie R.J., et al. Vascular reactivity is impaired in genetic females taking high-dose androgens. J. Am. Coll. Cardiol. 32 (1998) 1331-1335
12. New G., et al. Long-term estrogen therapy improves vascular function in male to female transsexuals. J. Am. Coll. Cardiol. 29 (1997) 1437-1444
13. Lieberman E.H., et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am. J. Cardiol. 78 (1996) 1210-1214
14. Vita J., and Keaney Jr. J.F. Hormone replacement therapy and endothelial function. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1867-1869
15. Kalantaridou S.N., et al. Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. Trends Endocrinol. Metab. 17 (2006) 101-109
16. Shaw L.J., et al. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. J. Am. Coll. Cardiol. 47 (2006) 4S-20S
17. Kuvin J.T., and Karas R. Clinical utility of endothelial function testing: ready for prime time?. Circulation 107 (2003) 3243-3247
18. Bonetti P.O., et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J. Am. Coll. Cardiol. 44 (2004) 2137-2141
19. Kuvin J.T., et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am. Heart J. 146 (2003) 168-174
20. Nohria A., et al. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J. Appl. Physiol. 101 (2006) 545-548
21. Loehr L.R., et al. Racial differences in endothelial function in postmenopausal women. Am. Heart J. 148 (2004) 606-611
22. Patel A.R., et al. Gender-based differences in brachial artery flow-mediated vasodilation as an indicator of significant coronary artery disease. Am. J. Cardiol. 96 (2005) 1223-1226
23. Joakimsen O., et al. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis. The Tromso Study. J. Clin. Epidemiol. 53 (2000) 525-530
24. Herrington D.M., et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1955-1961
25. Manson J.E., et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 13 (2006) 139-147
26. Hsia J., et al. Conjugated equine estrogens and coronary heart disease. Arch. Intern. Med. 166 (2006) 357-365
27. Grodstein F., et al. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Womens Health 15 (2006) 35-44
28. Prentice R., et al. Combined analysis of women's health initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am. J. Epidemiol. 163 (2005) 589-599
29. Hulley S., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
30. Mosca L., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
31. Harman S.M., et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8 (2005) 3-12
32. Vogel V., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 295 (2006) 2727-2741
33. Ensrud K., et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am. J. Cardiol. 97 (2006) 520-527
34. Couse J.F., and Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us?. Endocr. Rev. 20 (1999) 358-417
35. Moriarty K., et al. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 147 (2007) 5557-5563
36. Darblade B., et al. Estradiol alters nitric oxide production in the mouse aorta through the α-, but not β-, estrogen receptor. Circ. Res. 90 (2002) 413-419
37. Evinger III A.J., and Levin E.R. Requirements for estrogen receptor alpha membrane localization and function. Steroids 70 (2005) 361-363
38. Shearman A.M., et al. Association between estrogen receptor α gene variation and cardiovascular disease. JAMA 290 (2003) 2263-2270
39. Sudhir K., et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96 (1997) 3774-3777
40. Sudhir K., et al. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349 (1997) 1146-1147
41. Kjaergaard A.D., et al. Estrogen receptor α polymorphism and risk of cardiovascular disease, cancer, and hip fracture. Circulation 115 (2007) 861-871
42. Christian R.C., et al. Intimal estrogen receptor (ER) beta, but not ER alpha expression, is correlated with coronary calcification and atherosclerosis in pre-and postmenopausal women. J. Clin. Endocrinol. Metab. 91 (2006) 2713-2720
43. Liu P.Y., et al. Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery disease. J. Clin. Endocrinol. Metab. 90 (2005) 1041-1046
44. Zitzmann M., and Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int. J. Androl. 26 (2003) 76-83
45. Hamburg N.M., et al. Comparison of endothelial function in young men and women with a family history of premature coronary artery disease. Am. J. Cardiol. 94 (2004) 783-785
46. Hersberger M., et al. The CAG repeat polymorphism in the androgen receptor gene is associated with HDL-cholesterol but not with coronary atherosclerosis or myocardial infarction. Clin. Chem. 51 (2005) 1110-1115
47. Fratantonio E. Genetics of polycystic ovarian syndrome. Reprod. Biomed. Online 10 (2005) 713-720
48. New G., et al. Estrogen improves acetylcholine-induced but not metabolic vasodilation in biological males. Am. J. Physiol. 277 (1999) H2341-H2347
49. Sudhir K., and Komesaroff P.A. Cardiovascular actions of estrogens in men. J. Clin. Endocrinol. Metab. 84 (1999) 3411-3415
50. Liu P.Y., et al. Androgens and cardiovascular disease. Endocr. Rev. 24 (2003) 313-340
51. Dubey R.K., et al. Cardiovascular pharmacology of estradiol metabolites. J. Pharmacol. Exp. Ther. 308 (2004) 403-409
52. Barchiesi F., et al. 2-methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ. Res. 99 (2006) 266-274
53. Chatrath R., et al. Endothelium-dependent responses in coronary arteries are changed with puberty in male pigs. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H1168-H1176
54. Phillips G.B., et al. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler. Thromb. 14 (1994) 701-706
55. English K.M., et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur. Heart J. 21 (2000) 890-894
56. Orshal J.M., and Khalil R.A. Gender, sex hormones, and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286 (2004) R233-R249
57. Gerhard M., et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 98 (1998) 1158-1163
58. Canonico M., et al. Hormone therapy and venous thromboembolism among postmenopausal women. Circulation 115 (2007) 840-845
59. Anon. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273 (1995) 199-208
60. Borges S., et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80 (2006) 61-74
61. Goetz M.P., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23 (2005) 9312-9318
62. Lacut K., et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb. Haemost. 90 (2003) 124-131
63. Di Minno G., and Tufano A. Challenges in the prevention of venous thromboembolism in the elderly. J. Thromb. Haemost. 2 (2004) 1292-1298
64. Herrington D.M., et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1012-1017
65. Straczek C., et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration. Circulation 112 (2005) 3495-3500
66. Bray P.F., et al. Effect of genetic variations in platelet glycoproteins Ibα and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood 109 (2007) 1862-1869
67. Jayachandran M., et al. Platelet characteristics change with aging: role of estrogen receptor β. J. Gerontol. A. Biol. Sci. Med. Sci. 60 (2005) 815-819
68. Miller V.M., and Vanhoutte P.M. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am. J. Physiol. 261 (1991) R1022-R1027
69. Miller V.M., et al. Of mice, men, and hormones. Arterioscler. Thromb. Vasc. Biol. 24 (2004) R995-R997
70. Tsuchiya Y., et al. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 227 (2005) R115-R124